Roche’s Susvimo approved by European Commission for use in Europe
Roche said the European Commission approved Susvimo, its neovascular age-related macular degeneration treatment, for use in Europe based on data from three clinical studies.
Roche said Susvimo, a treatment for neovascular age-related macular degeneration affecting part of the eye, has been approved by the European Commission for use in Europe. The Swiss drugmaker said Monday the approval is based on data from three clinical studies on neovascular…